M&T Bank Corp Has $25.90 Million Holdings in Zoetis Inc. $ZTS

Key Points

• M&T Bank trimmed its stake in Zoetis by 5% in Q4 to 205,815 shares worth $25.90 million, and institutional investors now own about 92.8% of the company.
• Zoetis beat Q4 expectations with $1.48 EPS (vs. $1.40 est.) and $2.39B revenue, and set FY2026 guidance of 7.00–7.10 EPS (sell‑side consensus ~7.01).
• Zoetis declared a quarterly dividend of $0.53 ($2.12 annualized, ~1.9% yield) and holds an average analyst rating of "Hold" with a $151.75 average price target (7 Buy / 7 Hold / 1 Sell).

M&T Bank Corp decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 205,815 shares of the company's stock after selling 10,722 shares during the period. M&T Bank Corp's holdings in Zoetis were worth $25,896,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the 4th quarter worth about $25,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the fourth quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the third quarter valued at about $31,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the fourth quarter valued at about $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in Zoetis during the fourth quarter worth about $38,000. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 1.2%

Shares of ZTS opened at $112.81 on Tuesday. The company has a market capitalization of $47.45 billion, a P/E ratio of 18.74, a PEG ratio of 1.76 and a beta of 0.87. Zoetis Inc. has a one year low of $112.10 and a one year high of $172.23. The business's 50 day simple moving average is $119.93 and its 200-day simple moving average is $124.53. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 7.01 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis's dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZTS. UBS Group reduced their price objective on Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Bank of America boosted their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Friday, February 13th. Citigroup started coverage on shares of Zoetis in a research report on Wednesday, April 15th. They set a "buy" rating and a $145.00 target price on the stock. Piper Sandler restated a "neutral" rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, William Blair reiterated an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Zoetis currently has an average rating of "Hold" and an average price target of $151.75.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.